Navigation Links
Nanotech medicine, tumor tracking, new technologies and more
Date:7/14/2010

ne D Ruan " by D Ruan and P Keall will be at 10:24 a.m. on Tuesday, July 20 in room 204B of the Pennsylvania Convention Center.

ABSTRACT: http://www.aapm.org/meetings/amos2/pdf/49-13987-71074-176.pdf

This research was supported by the National Cancer Institute and the AAPM Seed Funding Initiative.


3) SIX-YEAR STUDY FINDS FEW PERMANENT SIDE EFFECTS AFTER SBRT FOR LUNG CANCER

A six-year study of lung cancer patients treated with stereotactic body radiation therapy (SBRT) found few people experienced significant lasting side effects from the relatively new technique.

SBRT hits tumors with extremely high (but narrowly focused) radiation doses, typically given in three to five treatments. The researchers evaluated lung density changes in 63 people who received SBRT between 2003 and 2009. After six months, patients had transient density increases of up to 100 percent compared to their pre-treatment lung density. After 12 months, the density changes stabilized to less than 50 percent of pre-treatment levels, and lung morphology was mostly unaffected.

"We saw some changes, but nothing of a catastrophic nature or anything that implies we're going in the wrong direction with this treatment," says co-author Brian Kavanagh, a professor of radiation oncology at the University of Colorado Denver School of Medicine. "The first impression is very much a reassuring one."

Understanding how normal lung tissue is affected by the intense radiation will help physicians avoid excess injury to healthy tissue and more aggressively treat tumors, says Kavanagh.

The researchers also discovered that some patients had subtle changes in normal tissue that appeared to signal later development of side effects such as inflammation.

"These early signals will give us an opportunity to anticipate potential problems and personalize treat
'/>"/>

Contact: Jason Socrates Bardi
jbardi@aip.org
858-775-4080
American Institute of Physics
Source:Eurekalert

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology news :

1. Bionanotechnology has new face, world-class future at Florida State
2. Chemist monitors nanotechnologys environmental impact
3. DNA nanotechnology breakthrough offers promising applications in medicine
4. Vigilance needed in nanotechnology
5. Biotech, nanotech and synthetic biology roles in future food supply explored
6. Engineers explore environmental concerns of nanotechnology
7. Conference to discuss future of nanotechnology enabled sensors
8. Novel nanotechnology heals abscesses caused by resistant staph bacteria
9. Nanotech protection
10. New Singapore-France research alliance to develop state-of-the-art nanotechnologies
11. Step forward for nanotechnology: Controlled movement of molecules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2015)... , May 18, 2015 Fingerprint ... sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if ... June until and including Q3 2015 and the sensors will ... . Communicated order values for 2015 hereby amount to 740 ... Q1 2015 of 140 MSEK and a number of smaller ...
(Date:5/11/2015)... May 11, 2015 Curemark LLC, a privately ... of a new Phase III double blind, randomized, placebo-controlled ... formulation, CM-AT, on all children ages 3-8 with Autism. ... Phase III double blinded clinical trial for CM-AT in ... of the digestive enzyme chymotrypsin. This new trial will ...
(Date:5/5/2015)... 5, 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, reminds investors and media that ... is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series ... is themed Global Fraud: Where is the Trust in ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... UC Davis cancer researchers have found that older men ... regular CT scans over lymph node removal are at ... last week in the journal Cancer, indicate that physicians ... when discussing treatment options with their patients. ...
... University of Washington physicists are detecting radioactivity from ... a mammoth March 11 earthquake, but the levels are ... health. On March 16, the scientists began testing ... Building on the UW campus, looking for evidence of ...
... is available in German . , Innovations relating ... presented by KIT at the 2011 Hannover Messe from April ... KIT will present a hybrid Porsche racing car, developments in ... InnoEnergy for a European energy supply system, and the Energy ...
Cached Biology News:Frequent CT scanning for testicular cancer surveillance associated with secondary malignancies 2Frequent CT scanning for testicular cancer surveillance associated with secondary malignancies 3Physicists detect low-level radioactivity from Japan arriving in Seattle 2Physicists detect low-level radioactivity from Japan arriving in Seattle 3KIT presents innovations at the 2011 Hannover Messe 2KIT presents innovations at the 2011 Hannover Messe 3KIT presents innovations at the 2011 Hannover Messe 4KIT presents innovations at the 2011 Hannover Messe 5
(Date:6/2/2015)... 2015 Research and Markets( http://www.researchandmarkets.com/research/7264hm/biomarkers ) ... report "Biomarkers - Technologies, Markets and Companies" ... follows the broad definition of a biomarker as ... evaluated as an indicator of normal biological or ... a therapeutic intervention. Tests based on biomarkers have ...
(Date:6/2/2015)... June 02, 2015 Research and Markets( http://www.researchandmarkets.com/research/l5jcdk/genotyping_market ... Market by Technology, Application & by Products - Global ... The global genotyping market is expected to reach ... at a CAGR of 22.3% during the forecast period ... be attributed to the availability of a range of ...
(Date:6/2/2015)... PAULO , June 2, 2015   Hospira, ... in biosimilars, today announced that its partner, Celltrion – a ... – the National Health Surveillance Agency in ... biosimilar monoclonal antibody approved for use in ... Hospira. Hospira also markets and sells biosimilar infliximab in ...
(Date:6/2/2015)... June 02, 2015 “Stem Cell Therapy to ... mainstream, and it is used often as an adjunct to ... practitioners are not yet aware or comfortable enough with the ... is most often reserved for the last resort cases - ... can barely lift a paw to get around. It is ...
Breaking Biology Technology:Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 2Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 3Genotyping Market Report 2015 by Technology, Application & by Products - Global Forecast to 2020 for the $17 Billion Market 2ANVISA Approves First Infliximab Biosimilar in Brazil 2ANVISA Approves First Infliximab Biosimilar in Brazil 3ANVISA Approves First Infliximab Biosimilar in Brazil 4ANVISA Approves First Infliximab Biosimilar in Brazil 5VetStem Biopharma, Proudly Announces a New Long Term Partnership with VCA West Los Angeles in Support of Stem Cell Therapy Training and Clinical Opportunities. 2VetStem Biopharma, Proudly Announces a New Long Term Partnership with VCA West Los Angeles in Support of Stem Cell Therapy Training and Clinical Opportunities. 3
... N.J., Sept. 21 Nuvilex, Inc. (OTC Bulletin Board: NVLX), ... with Reme-Flu(TM), will be incorporating Syn-X9(TM) proprietary delivery technology into ... to help prevent and treat flu-type symptoms resulting from influenza-like ... , , The unique attributes of the ...
... , ATLANTA, Sept. 21 CryoLife, Inc. (NYSE: ... to suburban Atlanta this week for the two-day Ross Summit ... of the Ross Procedure and to practice the technical nuances required to perform ... The Ross Procedure is a type of specialized aortic valve surgery in ...
... Mass., Sept. 21 Merrimack Pharmaceuticals, Inc., announced today that ... President, Development. Dr. Niyikiza comes to Merrimack from GlaxoSmithKline (GSK) ... oncology. Dr. Niyikiza has extensive drug development experience with ... pharmaceutical industry in which he has led ten New Drug ...
Cached Biology Technology:Nuvilex, Inc. Announced that Reme-Flu(TM) will Incorporate Proprietary Syn-X9(TM) Delivery Technology into its Product Formulation 2Nuvilex, Inc. Announced that Reme-Flu(TM) will Incorporate Proprietary Syn-X9(TM) Delivery Technology into its Product Formulation 3Leading Cardiovascular Surgeons Gather from Around the World to Share Ross Procedure Survival Data, Techniques at 2nd Annual Summit 2Leading Cardiovascular Surgeons Gather from Around the World to Share Ross Procedure Survival Data, Techniques at 2nd Annual Summit 3Leading Cardiovascular Surgeons Gather from Around the World to Share Ross Procedure Survival Data, Techniques at 2nd Annual Summit 4Leading Cardiovascular Surgeons Gather from Around the World to Share Ross Procedure Survival Data, Techniques at 2nd Annual Summit 5Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development 2
Eagle's Ham's amino acids; EHAA...
... active ingredient in Molecular Probes. SlowFadeAntifade ... to act as a free radical ... Our original SlowFade formulation (S-2828) was ... of fluorescein to almost zero (Figure ...
... System more than doubles the benefits of ... fast analysis cycles of the standard binary ... in tandem mode. Difficult separations are dramatically ... or heartcut configurations, on-line sample preparation is ...
... The PerkinElmer kit provides reagents for ... in serum and plasma samples using a ... samples are then neutralized and transferred to ... highly specific mouse monoclonal antibody to HIV-1 ...
Biology Products: